Publications of Daniel GUILLAUME
Bookmark and Share    
Full Text
See detailAn adapted test under a new light
DELRUE, Gaël ULiege; Harchies, Kim; Galluzzo, Audrey et al

Poster (2018, January)

Ecological lighting adaptation to reduce negelct symptoms

Detailed reference viewed: 50 (10 ULiège)
See detailFacilitating the use of an alternative pointing system for patients with multiple sclerosis with motor and cognitive impairments through procedural learning
MOYANO, Nicolas ULiege; DELRUE, Gaël ULiege; Gester, Elodie ULiege et al

Poster (2016, September)

We show that it's possible for people with MS with cognitive and motor impairments to use an alternative pointing system for their computer.

Detailed reference viewed: 33 (7 ULiège)
Full Text
See detailSafety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
van Pesch, Vincent; Bartholome, Emmanuel; Bissay, Veronique et al

in Acta Neurologica Belgica (2014), 114(3), 167-78

Natalizumab (Tysabri((R))) is highly efficacious in controlling disease activity in relapsing multiple sclerosis (MS) patients. As it is one of the more recent therapies for MS, there remains a need for ... [more ▼]

Natalizumab (Tysabri((R))) is highly efficacious in controlling disease activity in relapsing multiple sclerosis (MS) patients. As it is one of the more recent therapies for MS, there remains a need for long-term safety and efficacy data of natalizumab in a clinical practice setting. The Tysabri observational program (TOP) is an open-label, multicenter, multinational, prospective observational study, aiming to recruit up to 6,000 patients with relapsing-remitting MS from Europe, Canada and Australia. The objectives of this study are to collect long-term safety and efficacy data on disease activity and disability progression. We report here the interim results of the 563 patients included in TOP between December 2007 and 2012 from Belgium. This patient cohort was older at baseline, had longer disease duration, higher neurological impairment, and a higher baseline annualized relapse rate, when compared to patients included in the pivotal phase III AFFIRM trial. Nevertheless, the efficacy of natalizumab was comparable. The annualized relapse rate on treatment was reduced by 90.70 % (p < 0.0001) with a cumulative probability of relapse of 26.87 % at 24 months. The cumulative probabilities of sustained disability improvement and progression at 24 months were 25.68 and 9.01 %, respectively. There were no new safety concerns over the follow-up period. Two cases of progressive multifocal leukoencephalopathy were diagnosed. Our results are consistent with other observational studies in the post-marketing setting. [less ▲]

Detailed reference viewed: 36 (1 ULiège)